An LMU research team led by Professor Olivia M. Merkel, Chair of Drug Delivery at LMU, has developed a new delivery system ...

The Farapoint device adds another tool to the company’s pulsed field ablation portfolio that could help increase or sustain ...

The field of cancer immunotherapy has achieved remarkable progress, introducing strategies such as immune checkpoint inhibitors and adoptive cell therapies ...

As part of the first-in-human trial, participants received more than 15 times the standard dose of the chemotherapy drug doxorubicin every 21 days for up to one year. “Usually, a patient can only ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The hypertrophic cardiomyopathy ...

Cytokinetics Inc. won US approval for a drug to treat a deadly heart condition, posing a potential threat to sales of a similar Bristol Myers Squibb Co. treatment that’s expected to be a key growth ...

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or ...

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced ...

PFA has generated excitement among electrophysiologists who view it as an improvement over older thermal-based ablation approaches due to its potential for safer and faster procedures. The energy ...

Amy Bies was recovering in the hospital from injuries inflicted during a car accident in May 2007 when routine laboratory tests showed that her blood glucose and cholesterol were both dangerously high ...

LBA-5: A hospital policy of tranexamic acid to reduce transfusion in major non-cardiac surgery: The TRACTION trial ORLANDO, Fla., Dec. 9, 2025 /PRNewswire/ -- When hospitals were randomly assigned to ...